Profound Medical Corp.
(PROF)
undefined
undefined%
At close: undefined
7.40
0.14%
After-hours Dec 13, 2024, 03:59 PM EST
Company Description
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.
Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities.
The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids.
Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical Corp.
Country | CA |
IPO Date | Oct 29, 2019 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 131 |
CEO | Dr. Arun Swarup Menawat MBA, Ph.D. |
Contact Details
Address: 2400 Skymark Avenue Mississauga, ON CA | |
Website | https://www.profoundmedical.com |
Stock Details
Ticker Symbol | PROF |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001628808 |
CUSIP Number | 74319B502 |
ISIN Number | CA74319B5027 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Arun Swarup Menawat MBA, Ph.D. | Chairman of the Board & Chief Executive Officer |
Rashed Dewan | Chief Financial Officer |
Dr. Mathieu Burtnyk Ph.D. | President |
Levant Tinaz | Software Developer |
Matthew Sobczyk C.A., CPA | Assistant Corporate Controller |
Stephen Kilmer | Investor Relations |
Thomas Tamberrino MBA | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 11, 2024 | 6-K | Filing |
Dec 06, 2024 | 6-K | Filing |
Dec 06, 2024 | SUPPL | Filing |
Dec 06, 2024 | 6-K | Filing |
Dec 05, 2024 | 6-K | Filing |
Dec 05, 2024 | SUPPL | Filing |
Dec 05, 2024 | 6-K | Filing |
Dec 02, 2024 | 6-K | Filing |
Nov 26, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |